Sign in
Taking peopleNo phase

The PRECISION Partners Platform (P3) Study

Key facts

Who runs it
Imperial College London
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
850 people, planned
Started
23 Jun 2026
Expected to end
31 Dec 2029
Type of study
Observational, 3 groups
Record updated
18 November 2026

Who can take part

Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • For patients with CF, diagnosis confirmed by standard criteria
  • For patients with other forms of CSLD, a clinical diagnosis of either bronchiectasis (CT scan) or PCD (conventional criteria) will have been confirmed
  • Healthy volunteers will be colleagues and staff contacts (including children) at a participating centre i.e. Royal Brompton Hospital, or will be friends, family or contacts of patients
  • Ability to perform written informed consent (adults only)

Who cannot take part

  • Upper or lower respiratory tract infection symptoms within the previous 4 weeks (applicable only to healthy controls)
  • Asthma, or any other chronic respiratory disease (only applicable to healthy controls)
  • Current smoker/vaper, or ex-smoker/ vaper within the last 10 years (applicable to healthy controls only)
  • Inability to understand or cooperate with the test(s)
  • Inability to give informed consent, or withdrawal of informed consent (adults only)

This trial is currently available in United Kingdom.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Infections of the lungs are the most common problem for people with Cystic Fibrosis (CF), but also are significant in people with other lung conditions known generally as chronic suppurative lung diseases (CSLD), which can also cause recurrent chest infections. Some of the most common and severe infections are caused by Pseudomonas aeruginosa (Pa), Staphylococcus aureus (Sa), and Aspergillus fumigatus (Af). It is important to detect these early, in order to treat them and prevent damage to the lungs.

Read full original descriptionShow less

At the moment we rely on sputum culture or cough swabs, however, some people (for example small children or those with less severe disease) are not able to provide sputum, and cough swabs are less accurate. Additionally, although modulators such as Kaftrio and Ivacaftor have had significant positive effects on most people with CF taking them, these people often find they no longer produce sputum, and therefore we are not able to test for infections in the same way we did before. Studies have shown that although some people have fewer infections after starting modulators, they generally don't disappear altogether, and therefore we still need a reliable way to test for them.

Furthermore, we have seen that some people react differently to certain infections, and people with more than one infection simultaneously, also respond differently to these infections.

We would like to find new, reliable, easy and acceptable ways of testing for infections that does not require sputum and are acceptable for patients in order to detect, monitor and treat lung infections early. Additionally, we would like to better understand what causes the differing responses patients have to infections, in order to see if there are new ways we can target treatments.

The study is being undertaken in multiple centres across the UK in order to recruit a larger, more diverse and representative group of participants, than we would be able to achieve from one centre alone.

The 3 groups in the trial

  • People with Cystic Fibrosis (pwCF)

    500 people with Cystic Fibrosis (pwCF)

  • People with chronic suppurative lung disease (CSLD)

    Up to 100 patients with Chronic suppurative lung disease (CSLD)

  • Healthy control

    250 Healthy controls without CF, CSLD or other chronic respiratory disease

Next steps

For your doctor

Doctor ask sheet

A PDF summary of this trial for your doctor: what it tests, who can take part, its registry number and links, with room for notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The PRECISION Partners Platform (P3) Study: a Multi-centre, Multi-sample-type Approach to Establish Alternatives to Sputum Culture for Detecting Lung Infections in Cystic Fibrosis, and Better Understand Host/ Microbe Interactions.
Record updated
18 November 2026